-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.
-
Summary
-
Apellis Pharmaceuticals, Inc. quarterly Accounts Receivable, after Allowance for Credit Loss, Current history and growth rate from Q2 2021 to Q4 2024.
- Apellis Pharmaceuticals, Inc. Accounts Receivable, after Allowance for Credit Loss, Current for the quarter ending December 31, 2024 was $265M, a 28.3% increase year-over-year.
Accounts Receivable, after Allowance for Credit Loss, Current, Quarterly (USD)
Accounts Receivable, after Allowance for Credit Loss, Current, YoY Quarterly Growth (%)